NCT06304857
CardioPROTECTion with Dapagliflozin in Breast Cancer Patients Treated with AnthrAcycline - PROTECTAA TRIAL
Recruiting · Phase 3 · 4th Military Clinical Hospital with Polyclinic, Poland · registry updated 2024-12-04
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
The purpose of this study is to evaluate the effect of dapagliflozin on the incidence of cancer therapeutics-related cardiac dysfunction in patients with breast cancer receiving anthracycline treatment.
Inclusion
- Age \> 18 years and \< 80 years.
- Diagnosis of invasive breast cancer \[stage I-III\] and planned anthracycline treatment within 60 days.
- Signed Informed Consent to participate in the study.
Exclusion
- Urinary tract infection with the need for treatment with an antibiotic 48 hours before the scheduled start of anthracycline treatment.
- Recognised heart failure or symptoms which, in the opinion of the investigator may be a symptom of undiagnosed heart failure.
- Left ventricular ejection fraction \< 50% at the time of the screening.
- Severe valvular heart disease.
- A history of clinically significant arrhythmia, including atrial fibrillation regardless of type (at discretion of the investigator).
- A history of stroke.